Meletios A. Dimopoulos, MD; Hagop Kantarjian, MD; Elihu Estey, MD; Susan O'Brien, MD; Kay Delasalle, BS; Michael J. Keating, MBBS; Emil J. Freireich, MD; Raymond Alexanian, MD
Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, et al. Treatment of Waldenstrom Macroglobulinemia with 2-Chlorodeoxyadenosine. Ann Intern Med. 1993;118:195-198. doi: 10.7326/0003-4819-118-3-199302010-00007
Download citation file:
Published: Ann Intern Med. 1993;118(3):195-198.
To evaluate the activity of 2-chlorodeoxyadenosine (2CdA) in the treatment of patients with Waldenstrom macroglobulinemia.
Uncontrolled phase II trial.
Tertiary, referral cancer center.
Twenty-nine consecutive, symptomatic patients with Waldenstrom macroglobulinemia, of whom 9 were previously untreated.
2-Chlorodeoxyadenosine was administered as a continuous intravenous infusion at a dose of 0.1 mg/kg body weight per day for 7 days. Only two courses of 2CdA were given and responding patients were then followed without further treatment.
A total of 17 (59%) patients responded, including all of those who were newly diagnosed and 40% of those who had failed previous therapies. Treatment was well tolerated except for one death in a patient who had presented with severe pancytopenia. With a median follow-up of 7 months, only one responding patient has relapsed.
2-Chlorodeoxyadenosine is a nucleoside analog that was effective in most patients with Waldenstrom macroglobulinemia and was associated with little toxicity.
Learn more about subscription options.
Register Now for a free account.
Emergency Medicine, Hematology/Oncology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only